<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 10-year-old, female shih tzu was diagnosed as having <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) based on the presence of a nonregenerative <z:hpo ids='HP_0001903'>anemia</z:hpo>, dysplastic changes in the three hematopoietic cell lines, a <z:mpath ids='MPATH_458'>normal</z:mpath> to hypercellular bone marrow, and less than 30% blast cells of <z:hpo ids='HP_0000001'>all</z:hpo> nucleated cells in the bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>Low-dose aclarubicin, a differentiation-induction therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and atypical <z:hpo ids='HP_0001909'>leukemias</z:hpo> in humans, was administered </plain></SENT>
<SENT sid="2" pm="."><plain>Hematological improvement was observed, and the dog lived for 809 days after the first presentation </plain></SENT>
</text></document>